When Google hired Kai-fu Lee from Microsoft to set up the internet company's new R&D centre in Beijing in July, it set off a legal battle that highlights how much is at stake in the rush to cash in on the country's booming economy and vast scientific labour force.
British drug-delivery company Phoqus blamed "unfavourable market" conditions for meeting only its minimum target of £10 million in its initial public offering.
Celoxica, an Oxford University spin-out that makes chip design software, blamed “depressive market” conditions for the company raising less capital than it initially expected in its initial public offering
Intercell, an Austrian biotechnology company, has received a $1 million milestone payment from Merck for progress in the development of a bacterial vaccine candidate.
Nanonucleant, a spin-out of Imperial College London, is seeking angel financing to move ahead with a glass grain-based technology that aids in crystallising proteins for study as drug targets.
Despite the naysayers, more and more women are gaining success in the business of science. Our global investigation shows what it takes: good education, determination, a good employer, and some luck. Memo to government – Help them out.
Cambridge Antibody Technology Group Plc, which is traded on both the LSE and Nasdaq markets, said an agreement was struck at the 11th hour over a royalty dispute with Abbott Laboratories Inc.
Philips is seeking to boost adoption of its clock-less integrated circuit technology, offering it at a knockdown price to universities and research institutions.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.